(Q35587346)

9 August 2017

1 reference

title

Calcium antagonists and atherosclerosis protection in hypertension (English)

1 reference

9 August 2017

Calcium Antagonists and Atherosclerosis Protection in Hypertension (English)

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

3 April 2024

1 reference

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

3 April 2024

author name string

Rafael Hernández Hernández

1

1 reference

9 August 2017

María José Armas-Hernández

2

1 reference

9 August 2017

Manuel Velasco

3

1 reference

9 August 2017

María Cristina Armas-Padilla

5

1 reference

9 August 2017

Zafar H. Israili

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624278

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14624278

3 April 2024

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

http://journals.lww.com/00045391-200311000-00006

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

American Journal of Therapeutics

3 April 2024

published in

1 reference

9 August 2017

volume

10

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

409-414

1 reference

Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients

9 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

The role of calcium channel blockers in the treatment of hypertension

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Central sympathoinhibitory effects of calcium channel blockers

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Nisoldipine inhibits lipid peroxidation induced by coronary occlusion in pig myocardium.

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Antiperoxidant effects of dihydropyridine calcium antagonists

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Inhibition by nifedipine of the efflux of plasma low-density lipoprotein and albumin from the vasculature of the mouse mesentery in vivo

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Lipid peroxides as the initiating factor of atherosclerosis

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Antihypertensive and arterial anticalcinotic effects of calcium antagonists

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00006

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference